Andrea Necchi
@AndreaNecchi
Followers
4K
Following
3K
Media
688
Statuses
3K
Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Milano
Joined April 2012
Explore our #ESMO25 Top 5 updates 🔬💡👇 📌 IMA203, a PRAME-directed TCR therapy, demonstrates high response rates in uveal #melanoma 👉 https://t.co/OBhbBcYYhx
@DrSapnaPatel 📌 PSMAddition: 177Lu-PSMA-617 with ADT + ARPI in improves rPFS in #mHSPC 👉 https://t.co/VIiAgREIVR
1
3
8
Biomarkers for guiding #BladderCancer treatment decisions. @AndreaNecchi @SanRaffaeleMI and @UroDocAsh @MDAndersonNews discuss biomarkers in bladder cancer management. Dr. Necchi reviews immunotherapy biomarkers including tumor mutational burden (TMB), emphasizing its continuous
0
5
11
oncologyeducation.com
0
1
8
Disitamab vedotin + toripalimab vs chemotherapy in first-line locally advanced or metastatic #UrothelialCarcinoma with HER2-expression. Presentation by @AndreaNecchi @MyUniSR. #ESMO25 written coverage by @RKSayyid @UAUrology > https://t.co/bbJBqhT7nn
@myESMO
0
9
18
Phenomenal discussion by @AndreaNecchi on DV -tori in HER2+ mUC! @myESMO Masterful synthesis from disease biology to therapeutic relevance in #EVPembro era. "Polarization of cancer care" this can bridge global disparities in access to novel tx. @DrChoueiri @montypal @myESMO
0
6
19
Fantastic discussion @AndreaNecchi placing DV-T in context of metastatic urothelial cancer treatment — new combination and big player for Chinese markets. @myESMO @OncoAlert #ESMO25
#ESMOAmbassadors
0
24
59
Phenomenal discussion by @AndreaNecchi on DV -tori in HER2+ mUC! @myESMO Masterful synthesis from disease biology to therapeutic relevance in #EVPembro era. "Polarization of cancer care" this can bridge global disparities in access to novel tx. @DrChoueiri @montypal @myESMO
0
10
28
Neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab achieved high pathologic complete response and recurrence-free survival rates occurred in patients with MIBC. https://t.co/9DaS2i599v
#blcsm #ESMO25 | @AndreaNecchi
cancernetwork.com
Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.
0
1
2
Starting Presidential Session II #ESMO25 @myESMO @DrChoueiri Jun Guo Antonio Passaro @FAndreMD and Many more!
0
3
18
Learned so much from this #ESMO25 overview of existing ADCs in #bladdercancer by @AndreaNecchi in a session hosted @Silke_Gillessen & @drenriquegrande. The sheer number of trials examining ADCs in #bladdercancer is mind-boggling, incl multiple phase 3s.
1
14
39
Good to catch up with our stellar EBM @JCO_ASCO @yao_zhu_sh
What an incredible ESMO meeting! It was wonderful to experience such amazing science and catch up with so many friends. Together, we are making progress in the fight to improve survival for our patients in oncology.#ESMO25
0
2
7
What an incredible ESMO meeting! It was wonderful to experience such amazing science and catch up with so many friends. Together, we are making progress in the fight to improve survival for our patients in oncology.#ESMO25
0
3
9
Could not Miss the challenge of expert session so nicely chaired by our own @BrigidaMaiorano with Charles Nguyen. Second Line therapy of urothelial cancer has become quite complicated! @SanRaffaeleMI @MyUniSR @cityofhope @montypal @neerajaiims @SpiessPhilippe @UroDocAsh
1
8
24
I enjoyed so much the Poster walk #ESMO25 @myESMO showcasing the wave of data my team is presenting: - @vale_tateo HDCT in germ cell tumors from @TheEBMT database - @BrigidaMaiorano doublet vs triplet therapies in mHSPC - @Anto_cigliola outcomes of IO post IO in advances ccRCC
1
7
37
Starting off the day strong with @AndreaNecchi of @MyUniSR, who provided us with some amazing insights about primary findings from the SunRISe-4 and GDFather-NEO trials in #MIBC. To hear his exclusive commentary, keep an eye on our ongoing conference coverage at
0
3
4
Neoadjuvant spark by @AndreaNecchi with the GDFather-NEO Ph.II, blinded trial: nivolumab + GDF-15 Ab visugromab vs nivo + placebo. pCR : 33.3% vs 7.1%. MPR 66.7% vs 21.4%. Radiological response: ORR 60.0% vs 14.3%. #ESMO25 #BladderCancer @myESMO @OncoAlert @OncLive
0
14
33
Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab or cetrelimab alone in patients with #MIBC: #SunRISe4 primary analysis and biomarker results. Presentation by @AndreaNecchi @MyUniSR. #ESMO25 written coverage by @zklaassen_md @GACancerCenter >
1
10
17